Anixa Biosciences Inc (ANIX) SEC Filing 8-K Material Event for the period ending Monday, November 30, 2020

Anixa Biosciences Inc

CIK: 715446 Ticker: ANIX

View differences made from one to another to evaluate Anixa Biosciences Inc's financial trajectory

Compare SEC Filings Year-over-Year (YoY) and Quarter-over-Quarter (QoQ)
Sample 10-K Year-over-Year (YoY) Comparison

Compare this 8-K Corporate News to its predecessor by reading our highlights to see what text and tables were  removed  ,   added    and   changed   by Anixa Biosciences Inc.


Assess how Anixa Biosciences Inc's management team is paid from their Annual Proxy

Definitive Proxy Statement (Form DEF 14A)
Screenshot example of actual Proxy Statement

Anixa Biosciences Inc's Definitive Proxy Statement (Form DEF 14A) filed after their 2020 10-K Annual Report includes:

  • Voting Procedures
  • Board Members
  • Executive Team
  • Salaries, Bonuses, Perks
  • Peers / Competitors


Ticker: ANIX
CIK: 715446
Form Type: 8-K Corporate News
Accession Number: 0001493152-20-022761
Submitted to the SEC: Tue Dec 01 2020 3:30:33 PM EST
Accepted by the SEC: Tue Dec 01 2020
Period: Monday, November 30, 2020
Industry: Medical Laboratories
  1. New Agreement

External Resources:
Stock Quote
Social Media

Bookmark the Permalink: